WO2002040013A1 - Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin - Google Patents
Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin Download PDFInfo
- Publication number
- WO2002040013A1 WO2002040013A1 PCT/IT2001/000395 IT0100395W WO0240013A1 WO 2002040013 A1 WO2002040013 A1 WO 2002040013A1 IT 0100395 W IT0100395 W IT 0100395W WO 0240013 A1 WO0240013 A1 WO 0240013A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carnitine
- lactoferrin
- propionyl
- composition
- health food
- Prior art date
Links
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 47
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 47
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 47
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 47
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 47
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000010438 iron metabolism Effects 0.000 title claims abstract description 6
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 230000002107 myocardial effect Effects 0.000 claims abstract description 6
- 230000003617 peroxidasic effect Effects 0.000 claims abstract description 6
- 229930014626 natural product Natural products 0.000 claims abstract description 5
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 230000005856 abnormality Effects 0.000 claims abstract description 4
- 150000002632 lipids Chemical class 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 208000018152 Cerebral disease Diseases 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims abstract 10
- 235000015872 dietary supplement Nutrition 0.000 claims abstract 4
- 208000021908 Myocardial disease Diseases 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims description 19
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 15
- 210000003022 colostrum Anatomy 0.000 claims description 13
- 235000021277 colostrum Nutrition 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 claims description 6
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 5
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 239000005862 Whey Substances 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 239000005515 coenzyme Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229940098084 pyridoxine 5 mg Drugs 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 6
- 239000006196 drop Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 10
- 229960004857 mitomycin Drugs 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- -1 whey or colostrum Chemical compound 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000428352 Amma Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000016286 Iron metabolism disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
- A23V2250/54248—Lactoferrin
Definitions
- the present invention relates to a composition suitable for the prevention and/or treatment of peroxidative lipid disorders such as atherosclerosis, of myocardial and cerebral distress, of abnormalities related to iron metabolism and growth factor disorders, of bacterial and viral infections and of forms of cell degeneration.
- the composition is also suitable for regulating and stimulating the immune defences.
- the composition may take the form and exert the activity of an actual medicine, depending upon the support or preventive action or the strictly therapeutic action that the composition is intended to exert according to the particular individuals in whom it is to be used.
- composition according to the invention contains as its characterising ingredients:
- lactoferrin or a natural product containing lactoferrin such as whey or colostrum, or mixture thereof.
- L-carnitine The metabolic action both of L-carnitine and of the alkanoyl L-carnitines such as acetyl L-carnitine, propionyl L-carnitine, isovaleryl L-carnitine and butyryl L-carnitine is well known.
- Their function is very important for the production of energy, which takes place mainly through the intramitochondrial ⁇ -oxidation of fatty acids, the oxidation of branched-chain amino acids and the regulation of insulin activity.
- Also important is their protective activity against peroxidative phenomena which has been observed both at cerebral level and at myocardial and renal endothelial level.
- Another important property is their ability to stabilise cellular phospholipid membranes and the deformability of erythrocytes as well as the stimulation of erythropoietic activity.
- Lactoferrin too, like the “carnitines”, has a particular physiological role in the body, not only in the regulation of iron metabolism, but also in many mechanisms underlying the immune responses and operating against bacterial and viral infections.
- Lactoferrin which is regarded as belonging to the transferrin group, is a glycoprotein formed by 703 amino acids which is isolated both from cow's milk and human milk, and is above all present in high percentages in colostrum. As well as being present in milk, lactoferrin is also present in plasma, derived from neutrophils, in seminal fluid, in the mucous membranes, in tears and in sweat.
- Colostrum i.e. the mother's milk secreted immediately after childbirth, is particularly rich in lactoferrin, which constitutes 20% of the total proteins present in colostrum.
- the high lactoferrin content in colostrum is due to the fact that the immune defences in the newborn are weak and it is precisely lactoferrin that provides the organic defences. To this end it is important that it should not be degradable by tryptic enzymes and that it is well absorbed by the stomach.
- lactoferrin is present as a monoferric, diferric or iron-free structure.
- lactoferrin-beta and lactoferrin- amma with RNase activity
- lactoferrin-alpha without RNase activity
- lactoferrin Specific receptors for lactoferrin have been identified in intestinal tissue, in macrophages and monocytes, in neutrophils, in platelets and in certain bacteria.
- lactoferrin The antibacterial activity of lactoferrin is related above all to its ability to bind to iron and therefore to prevent the growth of those bacteria which need iron for their proliferation. In addition to its effect on bacterial growth, a further antibacterial action of lactoferrin has been demonstrated, caused by incorporation of lactoferrin in the bacterial membrane and consequent dispersion of the lipopolysaccharides of the bacterial wall with permanent alterations of its permeability. Lactoferrin, moreover, is capable of exerting an antifungal and antiviral effect, as well as of exerting an inhibiting effect on the growth of many forms of tumours and of regulating and enhancing the immune defences, especially when these are depressed or insufficient.
- lactoferrin has antioxidant ability, its inhibition of platelet aggregation and of the formation of thrombi, and its anticholesterolaemic activity.
- composition containing as its characterising components a combination of: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts; and
- lactoferrin or a natural product containing lactoferrin, selected from the group consisting of whey, colostrom or mixture thereof is extremely effective in the prevention and treatment of peroxidative lipid disorders such as atherosclerosis, of myocardial and cerebral distress, of abnormalities related to disorders of iron metabolism and growth factors, of bacterial and viral infections and forms of cell degeneration, and is also suitable for regulating and stimulating the immune defences owing to the potent synergistic effect exerted by its components.
- composition may also contain an additional "carnitine” selected from the group consisting of L-carnitine, acetyl L-carnitine, butyryl L- carnitine, valeryl L-carnitine and isovaleryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.
- an additional "carnitine” selected from the group consisting of L-carnitine, acetyl L-carnitine, butyryl L- carnitine, valeryl L-carnitine and isovaleryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.
- the weight-to-weight ratio of component (a) to component (b) ranges from 1:0.1 to 1:10, and preferably from 1:0.5 to 1:2.
- Lactoferrin + propionyl L-carnitine 7,000 ⁇ 420 6,200 ⁇ 410 6,000 ⁇ 425
- Lactoferrin 300 mg 2) Propionyl L-carnitine 100 mg Acetyl L-carnitine 100 mg L-carnitine 100 mg Lactoferrin 300 mg
- a pharmacologically acceptable salt of the various aforesaid carnitines mentioned in the present specification is, in addition to the respective “inner salts", any salt of these with an acid which does not give rise to unwanted toxic or side effects.
- These acids are well known to pharmacologists and to experts in pharmaceutical technology.
- Non-limiting examples of such salts are the following: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate; acid maleate; mucate; orotate; oxalate, acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.
- L-carnitine acid fumarate US 4,602,039
- acetyl L- carnitine mucate US 5,952,379
- isovaleryl L-carnitine acid fumarate US 5,227,578
- the supplement of the invention may further comprise vitamins, coenzymes, mineral substances, aminoacids and antioxidants.
- the supplement may be manufactured in the form of tablets, lozenges, capsules, pills, granulates, syrups, herb teas, vials or drops.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2001277688A AU2001277688A1 (en) | 2000-11-17 | 2001-07-24 | Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2000A000601 | 2000-11-17 | ||
| IT2000RM000601A IT1317937B1 (it) | 2000-11-17 | 2000-11-17 | Composizione per stimolare le difese immunitarie ed il metabolismo delferro comprendente una alcanoil l-carnitina e lattoferrina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002040013A1 true WO2002040013A1 (en) | 2002-05-23 |
Family
ID=11455001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IT2001/000395 WO2002040013A1 (en) | 2000-11-17 | 2001-07-24 | Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001277688A1 (it) |
| IT (1) | IT1317937B1 (it) |
| WO (1) | WO2002040013A1 (it) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060081A1 (en) * | 2003-01-07 | 2004-07-22 | N.V. Nutricia | A method of improving nutrient utilisation by a mammal and a composition for use therein |
| EP1466621A1 (en) * | 2001-12-28 | 2004-10-13 | NRL Pharma, Inc. | Compositions for improving lipid metabolism |
| WO2006001766A1 (en) * | 2004-06-23 | 2006-01-05 | Nestor Medical Ab | Composition comprising lactic acid and lactoferrin |
| WO2021221741A1 (en) * | 2020-04-28 | 2021-11-04 | Lonza Consumer Health Inc. | Nutritional composition comprising carnitine and method for treating or preventing an infection in a mammal |
| CN113645854A (zh) * | 2019-04-18 | 2021-11-12 | 西莫·拉西 | 预防或减少氧化应激和神经变性疾病的组合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0559425A1 (en) * | 1992-03-02 | 1993-09-08 | Immuno Japan Inc. | Formulated medicine for treatment and/or prevention of opportunistic infectious diseases complicated by infection with lentivirus |
| EP0753308A2 (en) * | 1995-07-12 | 1997-01-15 | Gambit International Limited | Use of lactoferrin for therapy of acute or recurrent infectious diseases by streptococcus pyogenes or other intracellular gram positive pathogen bacteria |
| WO1998001128A1 (en) * | 1996-07-05 | 1998-01-15 | Mendes S.R.L. | Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
-
2000
- 2000-11-17 IT IT2000RM000601A patent/IT1317937B1/it active
-
2001
- 2001-07-24 WO PCT/IT2001/000395 patent/WO2002040013A1/en active Application Filing
- 2001-07-24 AU AU2001277688A patent/AU2001277688A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0559425A1 (en) * | 1992-03-02 | 1993-09-08 | Immuno Japan Inc. | Formulated medicine for treatment and/or prevention of opportunistic infectious diseases complicated by infection with lentivirus |
| EP0753308A2 (en) * | 1995-07-12 | 1997-01-15 | Gambit International Limited | Use of lactoferrin for therapy of acute or recurrent infectious diseases by streptococcus pyogenes or other intracellular gram positive pathogen bacteria |
| WO1998001128A1 (en) * | 1996-07-05 | 1998-01-15 | Mendes S.R.L. | Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
Non-Patent Citations (8)
| Title |
|---|
| COFFEY M T ET AL: "CARNITINE STATUS AND LIPID UTILIZATION IN NEONATAL PIGLETS FED DIETS LOW IN CARNITINE 1, 2, 3", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 121, no. 7, 1991, pages 1047 - 1053, XP002061794, ISSN: 0022-3166 * |
| FILLEBEEN CARINE ET AL: "Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.", MOLECULAR BRAIN RESEARCH, vol. 72, no. 2, 1 October 1999 (1999-10-01), pages 183 - 194, XP001022494, ISSN: 0169-328X * |
| IKEDA M ET AL: "LACTOFERRIN MARKEDLY INHIBITS HEPATITIS C VIRUS INFECTION IN CULTURED HUMAN HEPATOCYTES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 245, 1998, pages 549 - 553, XP002923168, ISSN: 0006-291X * |
| KAJIKAWA MIKIO ET AL: "Lactoferrin inhibits cholesterol accumulation in macrophages mediated by acetylated or oxidized low-density lipoproteins.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1213, no. 1, 1994, pages 82 - 90, XP001036905, ISSN: 0006-3002 * |
| KAWAKAMI H ET AL: "EFFECT OF LACTOFERRIN ON IRON SOLUBILITY UNDER NEUTRAL CONDITIONS", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM. TOKYO, JP, vol. 57, no. 8, 1993, pages 1376 - 1377, XP002035374, ISSN: 0916-8451 * |
| KERNER J ET AL: "A STUDY OF THE ACYLCARNITINE CONTENT OF SOWS'COLOSTRUM, MILK AND NEWBORN PIGLET TISSUES;DEMONSTRATION OF HIGH AMOUNTS OF ISOVALERYL-CARNITINE IN COLOSTRUM AND MILK", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 114, no. 5, 1984, pages 854 - 861, XP002061795, ISSN: 0022-3166 * |
| ORLANDI A ET AL: "Propionyl-L-carnitine exerts a specific control on serum triglyceride levels and plaque progression in hypercholesteremic aged rabbits", AGE, AMERICAN AGING ASSOCIATION, CHESTER, PA, US, vol. 16, no. 3, July 1993 (1993-07-01), pages 117, XP002101595, ISSN: 0161-9152 * |
| PAULSON D J ET AL: "PROTECTION OF THE ISCHAEMIC MYOCARDIUM BY L-PROPIONYLCARNITINE: EFFECTS ON THE RECOVERY OF CARDIAC OUTPUT AFTER ISCHAEMIA AND REPERFUSION, CANITINE TRANSPORT, AND FATTY ACID OXIDATION", CARDIOVASCULAR RESEARCH, XX, XX, vol. 20, no. 7, 1986, pages 536 - 541, XP002042649, ISSN: 0008-6363 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1466621A1 (en) * | 2001-12-28 | 2004-10-13 | NRL Pharma, Inc. | Compositions for improving lipid metabolism |
| EP1466621A4 (en) * | 2001-12-28 | 2009-05-27 | Nrl Pharma Inc | COMPOSITIONS FOR ENHANCING LIPID METABOLISM |
| WO2004060081A1 (en) * | 2003-01-07 | 2004-07-22 | N.V. Nutricia | A method of improving nutrient utilisation by a mammal and a composition for use therein |
| WO2006001766A1 (en) * | 2004-06-23 | 2006-01-05 | Nestor Medical Ab | Composition comprising lactic acid and lactoferrin |
| CN113645854A (zh) * | 2019-04-18 | 2021-11-12 | 西莫·拉西 | 预防或减少氧化应激和神经变性疾病的组合物 |
| WO2021221741A1 (en) * | 2020-04-28 | 2021-11-04 | Lonza Consumer Health Inc. | Nutritional composition comprising carnitine and method for treating or preventing an infection in a mammal |
Also Published As
| Publication number | Publication date |
|---|---|
| ITRM20000601A0 (it) | 2000-11-17 |
| AU2001277688A1 (en) | 2002-05-27 |
| IT1317937B1 (it) | 2003-07-15 |
| ITRM20000601A1 (it) | 2002-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5290571A (en) | Biologically active whey protein concentrate | |
| US5230902A (en) | Undenatured whey protein concentrate to improve active systemic humoral immune response | |
| US6262019B1 (en) | Method of treatment of glutathione deficient mammals | |
| US6479069B1 (en) | Nutritional supplement for increased energy and stamina | |
| EP1455603B1 (en) | Stimulation of in vivo production of proteins with formulation comprising leucine | |
| EP0969744B1 (en) | Nutritional composition for improvements in cell energetics | |
| US7790209B2 (en) | Total enteral nutritious composition | |
| EP1117394B1 (en) | Use of carnitines and resveratrol to produce a composition for the prevention or therapeutic treatment of cerebral disorders brought about by ageing and use of neurotoxic drugs | |
| EP0374390A1 (en) | Whey protein composition, a method for producing it and application of the whey protein composition | |
| US20050143340A1 (en) | Adenosyl-cobalamin fortified compositions | |
| US4752619A (en) | Nutritional supplement for treatment of uremia | |
| WO2002040013A1 (en) | Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin | |
| CN110584120A (zh) | 骨健康组合物 | |
| EP1931223B1 (en) | Nutrition comprising betaine against muscle wasting | |
| AU778952B2 (en) | Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms | |
| MXPA02000911A (es) | Composicion para la prevencion y tratamiento de insuficiencias y enfermedades renales. | |
| RU2335927C2 (ru) | Обогащенные лейцином питательные композиции | |
| EP1599198B1 (en) | Potassium taurate bicarbonate and ascorbate complexes | |
| US20070031487A1 (en) | Nutritional supplement for women | |
| Mc Donagh et al. | Milk and dairy products for better human health | |
| EP3855944A1 (en) | Method and composition for increasing the bioavailability of carnitine | |
| MXPA01003569A (es) | Combinacion de carnitinas y resveratrol para prevenir o tratar enfermedades cerebrales y del envejecimiento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |